ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biologics

Lilly applies for emergency use authorization for COVID-19 antibody treatment

by Megha Satyanarayana
October 9, 2020 | APPEARED IN VOLUME 98, ISSUE 39

 

Eli Lilly and Company and Regeneron have applied to the US Food and Drug Administration for emergency use authorizations (EUAs) for their COVID-19 monoclonal antibodies, which block the entry of SARS-CoV-2 into human cells. Both firms have released early data from clinical trials showing that their antibodies reduce viral load and have some effect on symptoms. Regeneron, which provided its treatment to President Donald J. Trump, has said it will initially make the drug available for free; Lilly has said it would like to do the same.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment